CureVac NV
CVAC4.300USD
-0.010-0.23%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
968.24MMarket Cap
8.85P/E TTM
More Details of CureVac NV Company
CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
CureVac NV Info
Ticker SymbolCVAC
Company nameCureVac NV
IPO dateAug 14, 2020
CEOZehnder (Alexander)
Number of employees825
Security typeOrdinary Share
Fiscal year-endAug 14
AddressFriedrich-Miescher-Str. 15
CityTUEBINGEN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryGermany
Postal code72076
Phone49707198830
Websitehttps://www.curevac.com/
Ticker SymbolCVAC
IPO dateAug 14, 2020
CEOZehnder (Alexander)
Company Executives of CureVac NV
Name
Name/Position
Position
Shareholding
Change
Mr. Baron Jean Stephenne
Mr. Baron Jean Stephenne
Independent Chairman of Supervisory Board
Independent Chairman of Supervisory Board
40.49K
+141.65%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Member of the Supervisory Board
Member of the Supervisory Board
29.31K
+170.24%
Mr. Craig A. Tooman
Mr. Craig A. Tooman
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
27.79K
+187.92%
Mr. Michael Brosnan
Mr. Michael Brosnan
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
19.75K
+371.79%
Mr. Axel-Sven Malkomes
Mr. Axel-Sven Malkomes
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Klaus Schollmeier, Ph.D.
Dr. Klaus Schollmeier, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Dr. Malte Greune, Ph.D.
Dr. Malte Greune, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
--
--
Dr. Debra Barker, M.D.
Dr. Debra Barker, M.D.
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Dr. Alexander Zehnder, M.D.
Dr. Alexander Zehnder, M.D.
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Myriam Mendila, M.D.
Dr. Myriam Mendila, M.D.
Chief Scientific Officer, Member of the Management Board
Chief Scientific Officer, Member of the Management Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Baron Jean Stephenne
Mr. Baron Jean Stephenne
Independent Chairman of Supervisory Board
Independent Chairman of Supervisory Board
40.49K
+141.65%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Member of the Supervisory Board
Member of the Supervisory Board
29.31K
+170.24%
Mr. Craig A. Tooman
Mr. Craig A. Tooman
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
27.79K
+187.92%
Mr. Michael Brosnan
Mr. Michael Brosnan
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
19.75K
+371.79%
Mr. Axel-Sven Malkomes
Mr. Axel-Sven Malkomes
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Klaus Schollmeier, Ph.D.
Dr. Klaus Schollmeier, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
Switzerland
1.06M
85.06%
Belgium (Country)
186.00K
14.94%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Dec 16
Updated: Tue, Dec 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Glazer Capital, LLC
2.02%
Alpine Associates Management Inc.
1.02%
Qube Research & Technologies Ltd
0.76%
Bill & Melinda Gates Foundation
0.70%
AQR Capital Management, LLC
0.44%
Other
95.06%
Shareholders
Shareholders
Proportion
Glazer Capital, LLC
2.02%
Alpine Associates Management Inc.
1.02%
Qube Research & Technologies Ltd
0.76%
Bill & Melinda Gates Foundation
0.70%
AQR Capital Management, LLC
0.44%
Other
95.06%
Shareholder Types
Shareholders
Proportion
Hedge Fund
4.03%
Investment Advisor/Hedge Fund
2.87%
Investment Advisor
1.64%
Research Firm
0.89%
Foundation
0.70%
Pension Fund
0.16%
Bank and Trust
0.13%
Individual Investor
0.09%
Sovereign Wealth Fund
0.05%
Other
89.45%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
242
23.52M
11.47%
+45.36K
2025Q3
254
23.47M
13.08%
+8.57M
2025Q2
251
14.62M
11.55%
+3.90M
2025Q1
235
10.71M
11.20%
-14.51M
2024Q4
236
10.78M
11.68%
-1.77M
2024Q3
244
12.54M
12.61%
-3.08M
2024Q2
263
15.56M
13.23%
-3.38M
2024Q1
281
18.95M
13.33%
-10.95M
2023Q4
300
23.60M
17.13%
-11.99M
2023Q3
318
35.42M
18.08%
-1.78M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Glazer Capital, LLC
594.85K
0.26%
+594.85K
--
Jun 30, 2025
Alpine Associates Management Inc.
1.97M
0.88%
+1.97M
--
Jun 30, 2025
Qube Research & Technologies Ltd
1.18M
0.53%
+1.18M
--
Jun 30, 2025
Bill & Melinda Gates Foundation
1.57M
0.7%
-28.77K
-1.80%
Sep 30, 2024
Water Island Capital, LLC
957.03K
0.42%
+957.03K
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
580.38K
0.26%
-17.75K
-2.97%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
AltShares Merger Arbitrage ETF
1.3%
Virtus LifeSci Biotech Clinical Trials ETF
0.65%
NYLI Merger Arbitrage ETF
0.57%
Global X Genomics & Biotechnology ETF
0.56%
ProShares Ultra Nasdaq Biotechnology
0.15%
Invesco Nasdaq Biotechnology ETF
0.11%
SPDR S&P International Small Cap ETF
0.05%
iShares Biotechnology ETF
0.04%
iShares MSCI Europe Small-Cap ETF
0.04%
iShares MSCI EAFE Small-Cap ETF
0.02%
View more
AltShares Merger Arbitrage ETF
Proportion1.3%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.65%
NYLI Merger Arbitrage ETF
Proportion0.57%
Global X Genomics & Biotechnology ETF
Proportion0.56%
ProShares Ultra Nasdaq Biotechnology
Proportion0.15%
Invesco Nasdaq Biotechnology ETF
Proportion0.11%
SPDR S&P International Small Cap ETF
Proportion0.05%
iShares Biotechnology ETF
Proportion0.04%
iShares MSCI Europe Small-Cap ETF
Proportion0.04%
iShares MSCI EAFE Small-Cap ETF
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of CureVac NV?
The top five shareholders of CureVac NV are:
Glazer Capital, LLC holds 594.85K shares, accounting for 0.26% of the total shares.
Alpine Associates Management Inc. holds 1.97M shares, accounting for 0.88% of the total shares.
Qube Research & Technologies Ltd holds 1.18M shares, accounting for 0.53% of the total shares.
Bill & Melinda Gates Foundation holds 1.57M shares, accounting for 0.70% of the total shares.
Water Island Capital, LLC holds 957.03K shares, accounting for 0.42% of the total shares.
Glazer Capital, LLC holds 594.85K shares, accounting for 0.26% of the total shares.
Alpine Associates Management Inc. holds 1.97M shares, accounting for 0.88% of the total shares.
Qube Research & Technologies Ltd holds 1.18M shares, accounting for 0.53% of the total shares.
Bill & Melinda Gates Foundation holds 1.57M shares, accounting for 0.70% of the total shares.
Water Island Capital, LLC holds 957.03K shares, accounting for 0.42% of the total shares.
What are the top three shareholder types of CureVac NV?
The top three shareholder types of CureVac NV are:
Glazer Capital, LLC
Alpine Associates Management Inc.
Qube Research & Technologies Ltd
Glazer Capital, LLC
Alpine Associates Management Inc.
Qube Research & Technologies Ltd
How many institutions hold shares of CureVac NV (CVAC)?
As of 2025Q4, 242 institutions hold shares of CureVac NV, with a combined market value of approximately 23.52M, accounting for 11.47% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.61%.
What is the biggest source of revenue for CureVac NV?
In FY2025Q2, the -- business generated the highest revenue for CureVac NV, amounting to -- and accounting for --% of total revenue.
